BioCatalyst

Solriamfetol 150 mg, Solriamfetol 300 mg — catalyst calendar

2 verified catalyst event(s) referencing Solriamfetol 150 mg, Solriamfetol 300 mg, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 4mo
ESTIMATED
 READOUT
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using
Phase 3 · Binge-Eating Disorder
 AXSM Axsome Therapeutics, Inc. Solriamfetol 150 mg, Solriamfetol 300 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-12 (month)
in 4mo
ESTIMATED
 READOUT
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shif
Phase 3 · Excessive Sleepiness, Shift-work Disorder
 AXSM Axsome Therapeutics, Inc. Solriamfetol 150 mg, Solriamfetol 300 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.